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The Selenium and Vitamin E Cancer Prevention Trial (SELECT) 
was one of the largest human cancer prevention trials ever under- 
taken. Designed to examine the role of selenium and vitamin E in 
preventing prostate cancer (1) as a double-blind study, SELECT 
administered daily 200 micrograms of selenium in the form of 
pure L-seleilomethionine, 400 1IJ of synthetic D,L-a-tocopherol 
(vitamin E), a combination of these two components, or a placebo 
to four approximately equally divided groups. SELECT enrollinent 
was undertaken between A~tgust 22,2001 and June 24, 2004, and 
involved 35.533 healthy males from more than 425 participat- 
ing locations in the United States, Puerto Rico, and Canada. The 
baseline ages of males selected were fifty years or older for African 
Americans, and fifty-five years or older for all others. No signifi- 
cant differences in prostate cancer incidence were observed in 
any of the groups; hou~ever, slight but statistically non-significant 
incieases were observed in prostate cancer risk within the vita- 
min E group and in type 2 diabetes mellitus within the selenium 
group. Therefore, although SELECT was planned to include a 
twelve year intervention period, intervention was discontinued 
after a median period of 5.46 years (2). 
SELECT clearly establishes that selenium in the form of 
L-selenomethionine, when administered to the diet of healthy 
American males fifty years of age and older, does not prevent 
prostate cancer. This important observation raises questions as 
to why SELECT'S findings are different from those of earlier tri- 
als (3-8) and numerous animal studies (9, 10) that also employed 
selenium, but showed dramatic reductions in certain forms of 
cancer. For ex?mple, the Nu~ritional Prevention of Cancer (NPC) 
trial was undertaken to examine the role of selenium in prevent- 
ing skin cancer (5-7). Each patient taking part in the study had 
a prior incidence of skin basal and/or squainous cell carcinoma. 
Even though the NPC trial did not decrease skin cancer incidence 
(61, it found dramatic reductions in other fonns of cancer, as well 
as in cancer mortality NPC initially reported that prostate cancers 
were reduced 63%, colorectal cancers 58%, and lung cancers 48% 
(5). A subsequent analysis of the complete NPC trial data reported 
that selenium supplementation reduced total and prostate cancer 
incidence but did not reduce lung or colorectal cancer incidence 
significantly (6). In addition, NPC had two limitations: it involved 
Figure 1. Selenomethlonlne metabolism In mammals. Major metabolites of 
selenomethionine are shown. The incorporation of selenocysteine into protein 
by replacing cysteine is proposed by analogy to other organisms but has not 
been verified in humans. For further reading on selenomethionine metabolism 
see (23, 24). 
a relatively small number of subjects (1,312) and was initially 
planned to examine the role of selenium in skin cancer prevention, 
thus considering risk factors only for that endpoint in randomizing 
subjects. In spite of these factors, the NPC trial, along with the 
other studies noted above, provided the impetus for undertaking 
the much larger SELECT. Other trials (also noted above) employ- 
ing vitamin E provided the basis for using this vitamin in SELECT 
(3, 4, 8). An exciting anticipation for SELECT was the elucidation 
of many other possible roles of selenium and vitamin E in initigat- 
ing other cancer forms and or other diseases such as their roles in 
preventing cardiovascular disease. 
To understand what SELECT tells us about the role of sele- 
nium in cancer prevention, one should exanline differences and 
similarities between SELECT and the earlier clinical trials and take 
into consideration results from many laboratory animal studies, 
almost all of which have shown protective effects of selenium. 
Although the SELECT investigators addressed some of these ques- 
tions and possible reasons for the discrepancies, further analysis is 
appropriate. We see SELECT as differing from other clinical trials 
of selenium in two ways: it used a different foml of selenium, and 
it used subjects of higher selenium status. Because of our expertise 
in selenium rather than in vitamin E, this commentary focuses 
mainly on the role of selenium in cancer. 
SELECT used pure L-selenomethionine as the intervention 
agent (1, 2), whereas other human trials and animal studies have 
demonstrated anti-tumorigenic efficacy for selenite and selenium- 
enriched baker's yeast. Although L-selenomethionine represents 
the major form of selenium in high-selenium yeast, that product 
has been shown to include other chemical forms of selenium (1 1). 
Selenonlethionine provides selenium for selenoprotein biosynthe- 
1 Thls article IS a U S government work, and IS not subject to copyright In the Unlted States I 
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After All." We consider the 
m' widespread use of blanket 
statements regarding the null 
SELECT results to miss both 
the discrepancy noted above 
and the question raised by that 
discrepancy: that is, who can 
benefit from selenium supple- 
mentation? However, SET-ECT, 
when compared to other find- 
ings showing selenium as a 
cancer chemopreventivr agent. 
has taught us a great deal, and 
its results should both modify 
our understanding of the role 
of this element in cancer 
and suggest better strategies 
for targeting selenium to the 
human population. 
For the most part, human 
clinical trials have been under- 
taken with little understand- 
Figure 2. One outcome of SELECT Is the need for baslc studies to understand selenium biology. Three basic ing about how acts 
approaches are illustrated in the figure by a nucleotide sequence highlighting the need for additional human genetics at the molecular level and 
and polymorphism analyses, a mouse for the use of animal models and a protein structure for the functional analyses the overall potential 
of selenoproteins. 
consequences of administering 
sis via the transsulfuration pathway, but it can be diverted from this nutritional micronutrient to such a large number of individu- 
that pathway into general protein synthesis-in lieu of its sulfur- als. Recent studies have shown that some selenium-containing 
analog, methionine-and it can be used in a number of other ways proteins (selenoproteins), such as thioredoxin reductase 1 (TRl), 
(Figure 1). This differentiates selenomethionine from other sele- may have roles in preventing cancer, but once the malignancy is 
nium compounds, which cannot be so diverted and, therefore, are initiated, TR1 may actually contribute to progression of the disease 
methylated to lorn1 methylselenol, a presuinptive antitumorigenic [see (14) and references therein]. Other studies in mice have shown 
metabolite methylselenol (12). that selenium deficiency may inhibit some forms of cancer (15, 16). 
The subjects enrolled in SELECT had higher initial plasma Numerous studies involtlng human selenoproteins have shown 
levels of selenium than those in the &PC trial (135 ng/ml and 113 a direct correlation between one of the polymorphic forms and 
ng/ml, respectively). The subjects in the NPC trial were selected, cancer risk (1 7-20). These studies suggest the need to learn more 
in part, on the basis of their having relatively low serum seleniun~ about the biology of selenium before administering thls element to 
levels (5); it was in this cohort that seleniunl supplementation was humans in such large numbers involving clinical trials (Figure 2). 
effective in reducing cancer risks. Moreover, recent analyses show Furthermore, another factor to consider is the costs involved that 
that the treatment effect in the NPC trial was restricted to those are only a fraction in animal studies of what they are in human 
with lower baseline plasma selenium concentrations (6, 7). It is of clinical trials. 
interest to note that the serum selenium levels of individuals in Clearly, our understanding of selenium biology is, at the very 
most European countries, even those supplemented with selenium, least, incomplete. Only recently have we learned the mechanism 
3 are lower than in unsupplemented Americans (1.3). If selenium of selenocysteine biosynthesis in humans (21) and identified the 
r 
supplementation can reduce cancer risk in low-selenium subjects, human set of selenoprotein genes (22). Functions of at least half 
then Europe would have been a better place to conduct a cancer of these gene products are not known and the mechanism of 
prevention trial at the SELECT scale. the differential regulation of various selenoproteins with varylng 
The termination of the active intervention phase of SELECT selenium in the diet is still unresolved. Although much progress 
was widely featured in on-line and printed media, including well- has been made recently in understanding the role of polymorphic 
regarded newspapers such as The New York Timn, The Washington sites in selenoprotein genes, further studies are needed. A better 
Post, and USA Today. The American Association of Retired Persons understanding of selenium biology requires additional mechanis- 
published a short report titled "Selenium, Vitamin E Don't Help tic, genetic and other experimental approaches, which should be 
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